Compare Citius Pharmaceuticals Inc (CTXR) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Kinder Morgan Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Kinder Morgan Inc trades at $32.49 (market cap $71.81B). The key difference: Kinder Morgan Inc is far larger — about 5272.4× Citius Pharmaceuticals Inc's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Kinder Morgan Inc for 150 Days on average.
| CTXR | KMI | |
|---|---|---|
Market Cap | $13.62M | $71.81B |
Volume | 132,438 | 16,921,908 |
Sector | Health | Energy |
52-Week High | $1.82 | $34.31 |
52-Week Low | $0.48 | $25.84 |
Typical Hold Time | 17 Days | 150 Days |
Enterprise Value | $3.79M | $103.86B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Kinder Morgan (KMI) trades at $32.25, up 1.35% with a bullish technical outlook. The company reported strong earnings beats in recent quarters with Q2 2026 EPS of $0.37 beating expectations of $0.32. Revenue grew to $16.94B in 2025 with improving profit margins. Analyst consensus shows mixed sentiment with 47% buy ratings and a $37.20 price target, representing 15% upside potential. Recent news highlights the company's $6B-$7B growth pipeline and resilience amid energy market volatility.
KMI presents a compelling investment case with stable fee-based revenues, dividend yield of approximately 4%, and strong project backlog. However, risks include high debt levels ($29.66B long-term debt), exposure to energy market volatility, and competitive pressures. The stock offers income and growth potential but requires monitoring of debt management and energy sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
